FIELD MATRIX / 01—05
One label. Five evidence systems.
A cross-field comparison of mechanism, maturity, translation, and the point where each claim must stop.
In plain English
These compounds do not form a treatment ladder. They answer different research questions. Thymosin Alpha-1 changes immune signaling. Semaglutide activates a gut-hormone receptor tied to glucose and appetite. CJC-1295 stimulates the growth-hormone axis. NAD+ is a cellular coenzyme, not a peptide. PT-141 activates brain melanocortin receptors linked to sexual desire.
The evidence also sits at different levels. Semaglutide has large outcome trials. Bremelanotide has phase 3 trials and a narrow approved indication. Thymosin Alpha-1 has decades of study but a major recent sepsis trial that was negative [1]. CJC-1295 has small human studies showing hormone changes, without large clinical-outcome trials [16][17]. NAD+ precursor trials reliably raise blood NAD+, while broad human benefits remain uncertain [18]. Comparison is useful only when these differences remain visible. The right question is not “which is best?” It is “what claim did each study actually test, and how far can that result travel?”
The field matrix
| Compound | Scientific class | Primary system | Evidence maturity | Translation status | Claim limit |
|---|---|---|---|---|---|
| Thymosin Alpha-1 | Thymic immunomodulatory peptide | Dendritic cells, T cells, innate-adaptive interface | Mechanistic work, reviews, randomized and observational clinical studies | Marketed in several countries; no United States marketing approval [2] | Major sepsis phase 3 trial was null [1] |
| Semaglutide | GLP-1 receptor agonist peptide | Glucose regulation, appetite, gastric emptying | Large randomized outcome programs | Approved prescription medicine in defined indications | Product, population, and endpoint remain specific [9][10][11] |
| CJC-1295 | Long-acting GHRH analog | Pituitary GH and downstream IGF-1 | Small early human pharmacology studies | Investigational; no approved human indication | Hormone change is not proof of recovery, body composition, or longevity [16][17] |
| NAD+ | Endogenous redox coenzyme | Cellular energy and enzyme signaling | Precursor trials plus broad biochemical literature | Supplements and compounded contexts; not an approved drug | Blood NAD+ rise does not establish broad clinical benefit [18][19][22] |
| PT-141 | Cyclic melanocortin agonist | Central MC4R and MC3R signaling | Human imaging, phase 3 trials, label data | Approved as bremelanotide for a defined population and indication | Approval does not extend to general enhancement or research material [24][25][27] |
Mechanism: five different levers
Thymosin Alpha-1 acts at an immune interface. It can promote antigen presentation and T-cell responses while also engaging an IDO-dependent regulatory pathway [6]. Its direction depends on immune context.
Semaglutide activates a single receptor family with effects across the pancreas, gut, and brain. The outcome program links that mechanism to weight, cardiovascular, and kidney endpoints [9][10][11].
CJC-1295 activates the GHRH receptor at the pituitary. It raises growth hormone and IGF-1 while preserving pulsatile secretion [16][17]. The proximal response is established. Downstream health claims are not.
NAD+ is a substrate and electron carrier distributed through core cell biology. NMN and NR replenish the pool through salvage pathways [21]. This is not receptor agonism and not peptide signaling.
PT-141 activates melanocortin receptors in central circuits. Human imaging supports altered sexual cue processing [24]. Its pathway differs from peripheral vascular agents.
Evidence maturity: read the design
Semaglutide has the deepest outcome record here. STEP 1 included 1,961 participants [11]. SELECT included 17,604 [10]. FLOW included 3,533 [9]. These sizes support more stable estimates within their entry criteria and endpoints.
Bremelanotide has a narrower but mature file. Two phase 3 trials included 1,267 women with a defined condition [25]. The extension followed 684 participants and clarified tolerability [26].
Thymosin Alpha-1 presents a conflict resolved by study quality. An earlier severe-sepsis trial suggested a marginal signal [5]. The later double-blind phase 3 trial included 1,106 adults and found no mortality difference [1]. The later result should carry more weight for that question.
CJC-1295 studies establish pharmacokinetics and hormone response in small samples [15][16][17]. NAD+ precursor trials establish biomarker movement and selected functional signals [19][20][22]. Neither record supports sweeping clinical conclusions.
Clinical translation: approval is specific
Clinical translation means more than a positive study. It links a defined compound and formulation to manufacturing standards, a studied population, a labeled indication, warnings, and ongoing surveillance. Semaglutide and bremelanotide reached that stage for specified uses. Their approvals do not cover every formulation or public claim.
Thymalfasin has international approvals but no United States marketing approval [2]. That mixed jurisdictional status should be stated without treating either side as a universal judgment. CJC-1295 never reached approval. Its early pharmacology cannot fill the missing development program. NAD+ is more complex because it is endogenous and sold through supplement and compounded channels. The human evidence summarized here mostly concerns oral precursors, not every route marketed under the NAD+ name [18][19][22].
Status is not a ranking of scientific interest. It is a boundary on what can be claimed about a product in people.
Cautions: follow the mechanism and the record
Each file carries a different caution pattern. Thymosin Alpha-1 raises context questions wherever immune stimulation or immune suppression matters. Its usually mild local adverse effects do not resolve efficacy uncertainty [1][2][6]. Semaglutide’s dominant burden is gastrointestinal, with biliary disease and other monitored signals [12]. CJC-1295 raises mechanism-based concerns around sustained GH and IGF-1 exposure, while the larger problem is the absence of long-term trials [16][17]. NAD+ precursor studies support short-term tolerability in their tested settings, while the current review finds the broader human evidence incomplete [18][19][22]. Bremelanotide commonly causes nausea, flushing, and headache and carries a blood-pressure warning [26][27].
No shared “peptide safety” profile exists. Class, route, formulation, duration, manufacturing, population, and evidence quality all matter. The comparison stops there. It does not select a compound or recommend use.